Jardiance (Empagliflozin) Pediatric Safety: What Parents and Clinicians Need to Know for Children Under 12

Why Pediatric Empagliflozin Safety Matters Now

Childhood type 2 diabetes is no longer rare. Between 2001 and 2017, the prevalence of type 2 diabetes among U.S. youth aged 10 to 19 increased by 95%, according to CDC SEARCH study data 1. That acceleration has pushed clinicians to look beyond metformin and insulin for pediatric glycemic control.

Empagliflozin (brand name Jardiance), a sodium-glucose cotransporter 2 (SGLT2) inhibitor manufactured by Boehringer Ingelheim and Eli Lilly, earned its reputation in adults through the EMPA-REG OUTCOME trial. That study (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death among adults with type 2 diabetes and established cardiovascular disease 2. The adult safety profile is well-characterized after a decade of post-marketing surveillance. The pediatric profile is not. For children under 12, the evidence base is almost nonexistent, and parents searching for information deserve a clear account of what is known, what is extrapolated, and what remains genuinely unknown.

Current FDA Labeling: Who Is Approved and Who Is Not

The FDA expanded the Jardiance label in June 2023 to include pediatric patients aged 10 years and older with type 2 diabetes, based on results from the DINAMO trial 3. The approved doses are 10 mg and 25 mg once daily, identical to the adult formulation. No pediatric-specific formulation (liquid suspension or lower-dose tablet) exists.

Children under 10 are explicitly outside the approved labeling. The prescribing information does not provide dose recommendations, pharmacokinetic parameters, or safety data for this age group 3. This distinction matters. FDA pediatric approval requires either a completed pediatric trial or a waiver. Neither has occurred for children under 10 receiving empagliflozin. Any use below age 10 is off-label and unsupported by controlled trial evidence.

The heart failure and chronic kidney disease indications for Jardiance remain adult-only. The Pediatric Research Equity Act (PREA) may require future studies, but no active pediatric heart failure or CKD trial for empagliflozin is listed on ClinicalTrials.gov for children under 10 as of May 2026.

The DINAMO Trial: What It Showed and What It Did Not

The DINAMO study (NCT03429543) was a phase 3, randomized, double-blind trial comparing empagliflozin 10 mg, empagliflozin 25 mg, and linagliptin 5 mg against placebo in 158 pediatric patients aged 10 to 17 with type 2 diabetes 4. The primary endpoint was change in HbA1c from baseline at 26 weeks.

Results were modest. Empagliflozin 10 mg reduced HbA1c by 0.2 percentage points relative to placebo. The 25 mg arm showed a numerically larger reduction, though neither dose met the pre-specified significance threshold after multiplicity adjustment 4. For context, metformin monotherapy in the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) trial achieved approximately 0.5 to 1.0 percentage point HbA1c reductions in a similar age group 5.

Three facts limit the DINAMO trial's applicability to children under 12. First, no participant was younger than 10. Second, the sample size (158 total, roughly 40 per arm) lacked statistical power to detect rare adverse events. Third, the 26-week primary period, even with a 26-week extension, cannot address developmental safety over years of treatment during puberty and prepubescent growth.

Safety Signals From the DINAMO Data

The adverse event profile in DINAMO showed patterns consistent with the known SGLT2 inhibitor class effects, though in a much smaller dataset than adult trials.

Diabetic ketoacidosis (DKA) occurred in patients receiving empagliflozin but not in the placebo group 4. SGLT2 inhibitors lower the renal glucose threshold, which can mask hyperglycemia while ketone production continues. This euglycemic DKA pattern is well-documented in adults and carries particular danger in children, where caregivers may not recognize ketoacidosis without a blood glucose reading above 250 mg/dL.

The FDA's 2015 drug safety communication on SGLT2 inhibitors and DKA was based on adult post-marketing reports, identifying 73 cases across the SGLT2 class over a 20-month period 6. Pediatric DKA carries a higher morbidity burden than adult DKA. The Endocrine Society has noted, "Children with DKA are at substantially higher risk for cerebral edema than adults, and the consequences of delayed recognition are more severe" 7.

Genital mycotic infections (yeast infections) appeared more frequently in empagliflozin-treated adolescents, consistent with the glucosuric mechanism. Urinary tract infections were also reported. Volume depletion events, while uncommon, are a class concern for SGLT2 inhibitors and carry amplified risk in smaller patients with lower total blood volume.

Why Under-12 Safety Cannot Be Extrapolated From Adolescent Data

Extrapolating drug safety from a 16-year-old to a 7-year-old is not a minor step. It requires assumptions about renal maturation, body composition, pubertal hormone status, and hepatic metabolism that may not hold.

Glomerular filtration rate (GFR) does not reach adult-equivalent values until approximately age 2, but tubular function, including sodium-glucose cotransporter expression, continues to mature through childhood 8. SGLT2 inhibitors work by blocking glucose reabsorption in the proximal tubule. The density and activity of SGLT2 transporters in prepubescent children have not been characterized in published human studies. If transporter expression differs, both efficacy and toxicity could shift in unpredictable directions.

Body composition adds another variable. Children under 12 carry a higher ratio of total body water to lean mass compared to adolescents. A fixed 10 mg oral dose in a 25 kg child produces a very different mg/kg exposure than in a 70 kg teenager. No weight-based dosing algorithm for empagliflozin exists for any age group. The FDA-approved dose is a flat 10 mg or 25 mg.

Growth velocity is the third concern. Chronic glucosuria means caloric loss. A daily urinary glucose excretion of 60 to 80 grams (typical adult range on SGLT2 inhibitors) translates to 240 to 320 lost kilocalories 9. In a growing child with caloric needs of 1,400 to 1,800 kcal/day, that deficit represents 13% to 23% of total intake. No study has measured the effect of sustained empagliflozin-induced glucosuria on linear growth, bone mineral accrual, or pubertal progression in children under 12.

What the ADA and Endocrine Society Guidelines Recommend

The American Diabetes Association (ADA) 2024 Standards of Care, Section 14 ("Children and Adolescents"), recommends metformin as first-line pharmacotherapy for pediatric type 2 diabetes, with insulin for those presenting with ketosis, ketoacidosis, or HbA1c above 8.5% 10. The ADA acknowledges that empagliflozin and liraglutide now have pediatric FDA approvals but states that "long-term safety and efficacy data in youth are limited."

The Endocrine Society's 2023 clinical practice guideline on pediatric obesity-related comorbidities does not specifically recommend SGLT2 inhibitors for prepubescent children 7. The guideline reserves pharmacotherapy intensification for cases where metformin monotherapy and lifestyle intervention fail to achieve glycemic targets after 3 to 6 months.

The American Academy of Pediatrics (AAP) clinical practice guideline on pediatric type 2 diabetes (2023) states: "SGLT2 inhibitors may be considered in adolescents aged 10 and older when metformin is insufficient, but evidence in younger children does not support routine use" 11. That position reflects the absence of trial data rather than evidence of harm, but the distinction provides little comfort when clinical decisions must be made for individual patients.

Monitoring Requirements If Off-Label Use Is Considered

Some pediatric endocrinologists may consider off-label empagliflozin in selected children under 12 when all guideline-recommended options have failed. This section does not endorse that practice but outlines the monitoring framework that published literature and expert opinion suggest.

Blood ketone monitoring (beta-hydroxybutyrate) should be performed at home and in clinic. The DKA risk with SGLT2 inhibitors is not dose-dependent and can occur at any point during treatment 6. Parents need education on ketone meter use and sick-day rules. The standard sick-day instruction for SGLT2 inhibitors is to hold the drug during any acute illness, surgery, or prolonged fasting.

Renal function testing (serum creatinine and cystatin C-based eGFR) should occur at baseline, one month, and quarterly thereafter. Pediatric eGFR equations (Schwartz bedside formula) should be used rather than adult CKD-EPI 8.

Growth velocity tracking requires serial height, weight, and BMI-for-age measurements at minimum quarterly intervals, plotted on CDC growth charts. Any decline in height velocity percentile over two consecutive visits warrants drug discontinuation and reassessment. Bone age radiographs may be considered annually if treatment extends beyond 12 months.

Genital hygiene counseling is mandatory. Glucosuria predisposes to Candida vulvovaginitis and balanitis. Pediatric patients may not report symptoms spontaneously, so direct questioning at each visit is warranted.

HbA1c and continuous glucose monitoring (CGM) data should be reviewed at least quarterly. The goal is to confirm glycemic benefit proportionate to the risk assumed with off-label use.

Alternatives With Stronger Pediatric Evidence

Metformin remains the only oral diabetes medication with decades of pediatric safety data. The TODAY trial (N=699, ages 10 to 17) demonstrated that metformin alone maintained glycemic control in approximately half of participants over four years, with well-characterized gastrointestinal side effects and no growth impairment 5.

Liraglutide (Victoza), a GLP-1 receptor agonist, received FDA pediatric approval in 2019 for type 2 diabetes in patients aged 10 and older based on the Ellipse trial (N=135). That study showed a 0.64 percentage point HbA1c reduction relative to placebo at 26 weeks 12. Like empagliflozin, liraglutide has no data in children under 10.

Insulin (basal, prandial, or premixed) has no lower age limit and carries the longest safety track record in pediatric diabetes. Weight gain and hypoglycemia are the primary drawbacks, but these are manageable risks compared to the unknown developmental effects of a drug that has never been studied in the target age group.

For the child under 10 with type 2 diabetes who fails metformin, insulin remains the evidence-supported next step. This is not because SGLT2 inhibitors are proven harmful in younger children. It is because they are unproven, and the standard for accepting medication risk in a growing child should be higher than in an adult.

What Ongoing Research May Change

Boehringer Ingelheim's pediatric investigation plan (PIP) filed with the European Medicines Agency includes commitments to study empagliflozin in younger pediatric populations, but timelines for enrollment completion are not publicly available as of May 2026. The FDA's Pediatric Advisory Committee has discussed the need for longer-term SGLT2 inhibitor safety data in youth, particularly regarding bone health and reproductive development.

Post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) continues to collect pediatric safety signals. Clinicians who prescribe empagliflozin off-label in children under 12 should report adverse events through MedWatch to contribute to this limited dataset.

Real-world evidence from pediatric diabetes registries (SEARCH, RISE Pediatric) may provide observational safety data in the interim, though these studies were not designed to evaluate SGLT2 inhibitor outcomes specifically.

Until randomized trial data in children under 10 become available, the honest answer is that empagliflozin's safety in this population is unknown rather than established. The absence of reported harm is not the same as evidence of safety, particularly when the exposed population is vanishingly small. Clinicians should document the informed consent discussion, including the off-label status, when prescribing empagliflozin to any patient under 10 years of age.